Journal of Cancer Policy最新文献

{"title":"Corrigendum to “The use of the biosimilar drug can lead to large health care savings that can be reinvested for continued innovation: Analysis of consumption of an Italian health care company” [J. Cancer Pol. 40 (2024) 100473]","authors":"Francesco Ferrara, Maurizio Capuozzo, Roberto Langella, Ugo Trama, Eduardo Nava, Andrea Zovi","doi":"10.1016/j.jcpo.2024.100479","DOIUrl":"10.1016/j.jcpo.2024.100479","url":null,"abstract":"","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"41 ","pages":"Article 100479"},"PeriodicalIF":2.0,"publicationDate":"2024-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213538324000134/pdfft?md5=48244abdc80016cda2c858510cb39ebb&pid=1-s2.0-S2213538324000134-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142076968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sugar tax in Poland – Bittersweet lessons three years after implementation","authors":"Paweł Koczkodaj , Irmina Maria Michalek","doi":"10.1016/j.jcpo.2024.100483","DOIUrl":"10.1016/j.jcpo.2024.100483","url":null,"abstract":"","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"41 ","pages":"Article 100483"},"PeriodicalIF":1.3,"publicationDate":"2024-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140863531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Molecular profiling of brain tumors in LMICs: Achievable or impossible?","authors":"Hammad Atif Irshad , Taha Shaikh , Muhammad Shakir , Ahmed Gilani","doi":"10.1016/j.jcpo.2024.100481","DOIUrl":"https://doi.org/10.1016/j.jcpo.2024.100481","url":null,"abstract":"","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"40 ","pages":"Article 100481"},"PeriodicalIF":1.3,"publicationDate":"2024-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140816072","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Corrigendum to “The use of the biosimilar drug can lead to large health care savings that can be reinvested for continued innovation: Analysis of consumption of an Italian health care company” J. Cancer Policy. 40 (2024) 100473","authors":"Francesco Ferrara , Maurizio Capuozzo , Roberto Langella , Ugo Trama , Eduardo Nava , Andrea Zovi","doi":"10.1016/j.jcpo.2024.100480","DOIUrl":"10.1016/j.jcpo.2024.100480","url":null,"abstract":"","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"41 ","pages":"Article 100480"},"PeriodicalIF":2.0,"publicationDate":"2024-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213538324000146/pdfft?md5=8f5791b17a84ea7afdad2d4ba8d00080&pid=1-s2.0-S2213538324000146-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142076967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Understanding breast cancer patient pathways and their impact on survival in Mexico","authors":"Fatin Izzati Ramli ,&nbsp;Praveen Thokala ,&nbsp;Thaison Tong ,&nbsp;Karla Unger-Saldaña","doi":"10.1016/j.jcpo.2024.100482","DOIUrl":"10.1016/j.jcpo.2024.100482","url":null,"abstract":"<div><h3>Background</h3><p>Understanding patient pathways from discovery of breast symptoms to treatment start can aid in identifying ways to improve access to timely cancer care. This study aimed to describe the patient pathways experienced by uninsured women from detection to treatment initiation for breast cancer in Mexico City and estimate the potential impact of earlier treatment on patient survival.</p></div><div><h3>Methods</h3><p>We used process mining, a data analytics technique, to create maps of the patient pathways. We then compared the waiting times and pathways between patients who initially consulted a private service versus those who sought care at a public health service. Finally, we conducted scenario modelling to estimate the impact of early diagnosis and treatment on patient survival.</p></div><div><h3>Results</h3><p>Our study revealed a common pathway followed by breast cancer patients treated at the two largest public cancer centres in Mexico City. However, patients who initially sought care in private clinics experienced shorter mean wait times for their first medical consultation (66 vs 88 days), and diagnostic confirmation of cancer (57 vs 71 days) compared to those who initially utilized public clinics. Our scenario modelling indicated that improving early diagnosis to achieve at least 60% of patients starting treatment at early stages could increase mean patient survival by up to two years.</p></div><div><h3>Conclusion</h3><p>Our study highlights the potential of process mining to inform healthcare policy for improvement of breast cancer care in Mexico. Also, our findings indicate that reducing diagnostic and treatment intervals for breast cancer patients could result in substantially better patient outcomes.</p></div><div><h3>Policy summary</h3><p>This study revealed significant differences in time intervals along the pathways of women with breast cancer according to the type of health service first consulted by the patients: whether public primary care clinics or private doctors. Policies directed to reduce these inequities in access to timely cancer care are desperately needed to reduce socioeconomic disparities in breast cancer survival.</p></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"40 ","pages":"Article 100482"},"PeriodicalIF":1.3,"publicationDate":"2024-04-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140784903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Implications of FDA’s marketing authorization of hereditary cancer testing","authors":"David J. Benjamin ,&nbsp;Mark P. Lythgoe ,&nbsp;Arash Rezazadeh Kalebasty","doi":"10.1016/j.jcpo.2024.100478","DOIUrl":"https://doi.org/10.1016/j.jcpo.2024.100478","url":null,"abstract":"","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"40 ","pages":"Article 100478"},"PeriodicalIF":1.3,"publicationDate":"2024-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140632659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cervical cancer prevention in Southern Africa: A review of national cervical cancer screening guidelines in the Southern African development community","authors":"RA Adams ,&nbsp;MH Botha","doi":"10.1016/j.jcpo.2024.100477","DOIUrl":"https://doi.org/10.1016/j.jcpo.2024.100477","url":null,"abstract":"<div><h3>Background</h3><p>Cervical cancer poses a significant burden, particularly in low-and-middle income countries (LMIC) with limited access to healthcare. High-income countries have made progress in prevention, while LMIC face unacceptably high incidence and mortality rates, often lacking official screening recommendations. We analysed the presence and content of cervical cancer screening guidelines for the secondary prevention of cervical cancer in the Southern African Development Community (SADC) and compared it to the current World Health Organization (WHO) guidelines for screening and treatment of cervical pre-cancer lesions for cervical cancer prevention.</p></div><div><h3>Methods</h3><p>A review of national cervical cancer guidelines across the SADC region was conducted. Data was obtained from government websites, international cancer control platforms, and WHO resources. Search terms included \"cervical cancer\" and \"cervical cancer control guidelines\", amongst others. There were no limitations on publication years, and the most recent versions of the guidelines were analysed, regardless of language. Each guideline was assessed for specific screening and treatment recommendations, in relation to the current WHO guidelines. Points were assigned for each data element.</p></div><div><h3>Results</h3><p>While most countries contributed data to this analysis there was a notable absence of adherence to the WHO guidelines. The most common screening method was naked eye visual inspection. There was a consensus on the age of screening initiation. Most countries recommended treatment by cryotherapy and loop excision.</p></div><div><h3>Conclusion</h3><p>Effective cervical cancer screening programmes, guided by evidence-based recommendations, can enhance early intervention and outcomes. This study highlights the need for standardized and evidence-based cervical cancer screening guidelines in the SADC region, to reduce the burden of cervical cancer and improve the health outcomes of women in these areas.</p></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"40 ","pages":"Article 100477"},"PeriodicalIF":1.3,"publicationDate":"2024-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S2213538324000110/pdfft?md5=15c65f0633eb3cc72c112df9ff358dc5&pid=1-s2.0-S2213538324000110-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140548941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"INDIGO: Example of inappropriate crossover and why PFS cannot be the primary outcome in gliomas","authors":"Miguel Zugman ,&nbsp;Alyson Haslam ,&nbsp;Vinay Prasad","doi":"10.1016/j.jcpo.2024.100476","DOIUrl":"https://doi.org/10.1016/j.jcpo.2024.100476","url":null,"abstract":"","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"40 ","pages":"Article 100476"},"PeriodicalIF":1.3,"publicationDate":"2024-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140558666","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Six country vignettes: Strengthening radiotherapy and theranostics","authors":"Miriam Mikhail-Lette ,&nbsp;Lisbeth Cordero ,&nbsp;Yolande Lievens ,&nbsp;Akram Al-Ibraheem ,&nbsp;Jean-Luc Urbain ,&nbsp;Bhishamjit Chera ,&nbsp;Kristoff Muylle ,&nbsp;Aude Vaandering ,&nbsp;Arthur Accioly Rosa ,&nbsp;Juliano Julio Cerci ,&nbsp;Mike Sathekge ,&nbsp;Minjmaa Minjgee ,&nbsp;Erdenekhuu Nansalmaa ,&nbsp;Sereegotov Erdenechimeg ,&nbsp;Rolando Loría Ruiz ,&nbsp;Andrew Scott ,&nbsp;Diana Paez ,&nbsp;Francesco Giammarile ,&nbsp;Anna Veduta ,&nbsp;Erika Minoshima ,&nbsp;May Abdel-Wahab","doi":"10.1016/j.jcpo.2024.100471","DOIUrl":"10.1016/j.jcpo.2024.100471","url":null,"abstract":"<div><h3>Background</h3><p>For cancer patient populations worldwide, the synchronous scale-up of diagnostics and treatments yields meaningful gains in survival and quality of life. Among advanced cancer therapies, radiotherapy (RT) and theranostics are key to achieving practical, high-quality, and personalized precision medicine - targeting disease manifestations of individual patients and broad populations, alike. Aiming to learn from one another across different world regions, the six country vignettes presented here depict both challenges and victories in <em>de novo</em> establishment or improvement of RT and theranostics infrastructure.</p></div><div><h3>Methods</h3><p>The International Atomic Energy Agency (IAEA) convened global RT and theranostics experts from diverse world regions and contexts to identify relevant challenges and report progress in their own six countries: Belgium, Brazil, Costa Rica, Jordan, Mongolia, and South Africa. These accounts are collated, compared, and contrasted herein.</p></div><div><h3>Results</h3><p>Common challenges persist which could be more strategically assessed and addressed. A quantifiable discrepancy entails personnel. The estimated radiation oncologists (ROs), nuclear medicine physicians (NMPs), and medical physicists (MPs for RT and nuclear medicine) per million inhabitants in the six collective countries respectively range between 2.69–38.00 ROs, 1.00–26.00 NMPs, and 0.30–3.45 MPs (Table 1), reflecting country-to-country inequities which largely match World Bank country-income stratifications.</p></div><div><h3>Conclusion</h3><p>Established goals for RT and nuclear medicine advancement worldwide have proven elusive. The pace of progress could be hastened by enhanced approaches such as more sustainably phased implementation; better multinational networking to share lessons learned; routine quality and safety audits; as well as capacity building employing innovative, resource-sparing, cutting-edge technologic approaches.</p><p>Bodies such as ministries of health, professional societies, and the IAEA shall serve critical roles in convening and coordinating more innovative RT and theranostics translational research, including expanding nuanced global database metrics to inform, reach, and potentiate milestones most meaningfully.</p></div><div><h3>Policy Summary</h3><p>Aligned with WHO 25×25 NCDs target; WHA70.12 and WHA76.5 resolutions.</p></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"40 ","pages":"Article 100471"},"PeriodicalIF":1.3,"publicationDate":"2024-03-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140332160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development of a rapid tool for screening financial toxicity based on the comprehensive score for financial toxicity","authors":"Ling-ling Wang ,&nbsp;Richard Huan Xu","doi":"10.1016/j.jcpo.2024.100475","DOIUrl":"https://doi.org/10.1016/j.jcpo.2024.100475","url":null,"abstract":"<div><h3>Objective</h3><p>This study aimed to use item response theory (IRT) to develop and validate a short version of the Chinese COmprehensive Score for financial Toxicity (COST-S-C) in patients with cancer.</p></div><div><h3>Methods</h3><p>A total of 500 patients with cancer participated in the survey. Confirmatory factor analysis (CFA) was used to assess the factor structure of the COST-S-C. A two-parameter IRT model was used to examine the item fit of the COST-S-C. Item discrimination, item characteristic curves (ICCs), item information curves (IICs), and item fit were estimated. Differential item functioning (DIF) was assessed for participants’ gender and age. Reliability, convergent and discriminant validity was examined as well as estimating the optimal cut-off points of the COST-S-C.</p></div><div><h3>Results</h3><p>The CFA results supported the bi-factor structure of the COST-S-C. The IRT analysis findings revealed that several items showed problems with the ICCs, providing little information in terms of IICs as well as poor discrimination. Item 5 showed a negligible DIF problem with age. A valid 3-item COST-S-C scale and its optimal cut-off point was developed.</p></div><div><h3>Conclusions</h3><p>The COST-S-C is a valid and quick screening tool used to distinguish patients with cancer who report significant financial toxicity in various medical settings.</p></div>","PeriodicalId":38212,"journal":{"name":"Journal of Cancer Policy","volume":"40 ","pages":"Article 100475"},"PeriodicalIF":1.3,"publicationDate":"2024-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140321023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}